Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer ’s drug experienced brain bleeding or swelling, though many cases were asymptomatic.
Source: NYT Health - Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Clinical Trials Aduhelm (Drug) Alzheimer ' s Disease Labeling and Labels (Product) Brain Elderly Deaths (Fatalities) Biogen Inc Food and Drug Administration JAMA Neurology (Journal) RBC Source Type: news
More News: Alzheimer's | Bleeding | Brain | Clinical Trials | Food and Drug Administration (FDA) | Health | Neurology | Neuroscience | Science